Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.82 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.82 |
| ▸ | MTOR | P42345 | 1/20 | 0.82 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.60 |
| ▸ | MARK3 | P27448 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | NEK4 | P51957 | 1/20 | 0.60 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363239 | 0.91 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL3600534 | 0.91 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL3604209 | 0.80 | IRAK4 (0.79) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956628 | 0.78 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL16261073 | 0.77 | MTOR (0.74) | IRAK4IRAK1MTORKDM4ENPSR1 | |
| SCHEMBL29827291 | 0.77 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956620 | 0.77 | IRAK4 (0.89) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL25956637 | 0.76 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL18427725 | 0.76 | IRAK4 (1.00) | IRAK4IRAK1MTORDYRK3ROCK2 | |
| SCHEMBL13500540 | 0.76 | OPRK1 (0.86) | IRAK4IRAK1MTORKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4185279-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Secura Bio, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-105102000-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-2914296-B2 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3003309-B1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-2914296-B1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| CN-105682658-A | Treatment of cancers using pi3 kinase isoform modulators | 无限药品公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2424531-A2 | IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER | PamGene B.V. (NL) | 2012-03-07 | — | — | EP | disclosed |
| US-20120035076-A1 | IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2012-02-09 | — | — | US | disclosed |
| WO-2010121834-A2 | IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER | PAMGENE B.V. (NL) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243481-A1 | Irak kinase family as novel drug target for Alzheimer | PamGene B.V. (NL) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | IRAK4 495/4885IRAK1 361/4885MTOR 83/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | IRAK4 658/4885IRAK1 754/4885MTOR 280/4885 |
| US-20160024051-A1 | SALTS AND SOLID FORMS OF ISOQUINOLINONES AND COMPOSITION COMPRISING AND METHODS OF USING THE SAME | PIK3CA, PIK3CD, JAK2 | IRAK4 527/4885IRAK1 460/4885MTOR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.